At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
LXRX Lexicon Pharmaceuticals
Trading 11-22 12:04:18 EST
0.8627
+0.0910
+11.79%
High0.8700Low0.7300Vol6.18M
Open0.7430D1 Closing0.7717Amplitude18.14%
Mkt Cap311.86MTradable Cap157.13MTotal Shares361.49M
T/O4.94MT/O Rate3.39%Tradable Shares182.14M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--
HC Wainwright Cuts Price Target on Lexicon Pharmaceuticals to $4 From $6, Maintains Buy Rating
MT Newswires Live  ·  20 minutes ago
HC Wainwright Cuts Price Target on Lexicon Pharmaceuticals to $4 From $6, Maintains Buy Rating
BUZZ-Lexicon Pharmaceuticals rises on plan to lay off 60% of employees
Reuters  ·  26 minutes ago
BUZZ-Lexicon Pharmaceuticals rises on plan to lay off 60% of employees
Lexicon price target lowered to $4 from $6 at H.C. Wainwright
TIPRANKS  ·  34 minutes ago
Lexicon price target lowered to $4 from $6 at H.C. Wainwright
Lexicon Pharmaceuticals, Inc. : H.c. Wainwright Cuts Target Price to $4 From $6
THOMSON REUTERS  ·  37 minutes ago
Lexicon Pharmaceuticals, Inc. : H.c. Wainwright Cuts Target Price to $4 From $6
Lexicon Pharmaceuticals to Cut 60% of Workforce
MT Newswires Live  ·  11-22 21:43
Lexicon Pharmaceuticals to Cut 60% of Workforce
UPDATE 1-Lexicon Pharmaceuticals to lay off 60% of workforce after FDA setback
Reuters  ·  11-22 21:11
UPDATE 1-Lexicon Pharmaceuticals to lay off 60% of workforce after FDA setback
Lexicon Pharmaceuticals to Slash 60% of Jobs, Close Commercial Operations as Part of Reorganization
Dow Jones  ·  11-22 21:04
Lexicon Pharmaceuticals to Slash 60% of Jobs, Close Commercial Operations as Part of Reorganization
Lexicon falls on restructuring program
seekingalpha  ·  11-22 21:02
Lexicon falls on restructuring program
Lexicon Pharmaceuticals to cut workforce by 60% to focus on drug development
Reuters  ·  11-22 20:43
Lexicon Pharmaceuticals to cut workforce by 60% to focus on drug development
Lexicon to eliminate commercial organization, focus on clinical development
TIPRANKS  ·  11-22 20:40
Lexicon to eliminate commercial organization, focus on clinical development
BRIEF-Lexicon To Reposition As Clinical Development-Focused Company Following Regulatory Update From FDA
Reuters  ·  11-22 20:36
BRIEF-Lexicon To Reposition As Clinical Development-Focused Company Following Regulatory Update From FDA
Lexicon Pharmaceuticals Inc: Prioritizing Strong R&D Pipeline Including Ongoing Studies in Dpnp, HCM and Obesity
THOMSON REUTERS  ·  11-22 20:32
Lexicon Pharmaceuticals Inc: Prioritizing Strong R&D Pipeline Including Ongoing Studies in Dpnp, HCM and Obesity
Lexicon Pharmaceuticals Inc: Implementing Strategic Restructuring to Eliminate Commercial Organization and Rationalize Operations Across All Functions
THOMSON REUTERS  ·  11-22 20:32
Lexicon Pharmaceuticals Inc: Implementing Strategic Restructuring to Eliminate Commercial Organization and Rationalize Operations Across All Functions
Lexicon Pharmaceuticals Inc: Total Reduction of Approximately 60 Percent of Employees, Effective for Most Affected Employees by December 31
THOMSON REUTERS  ·  11-22 20:32
Lexicon Pharmaceuticals Inc: Total Reduction of Approximately 60 Percent of Employees, Effective for Most Affected Employees by December 31
Lexicon to Reposition as Clinical Development-Focused Company Following Regulatory Update From FDA
THOMSON REUTERS  ·  11-22 20:32
Lexicon to Reposition as Clinical Development-Focused Company Following Regulatory Update From FDA
Lexicon Pharmaceuticals Inc: Elimination of Promotional Efforts for Inpefa, Planned Commercial Activities for Zynquista
THOMSON REUTERS  ·  11-22 20:32
Lexicon Pharmaceuticals Inc: Elimination of Promotional Efforts for Inpefa, Planned Commercial Activities for Zynquista
Lexicon Pharmaceuticals Inc: Efforts Expected to Reduce 2025 Operating Costs by $100 Mln
THOMSON REUTERS  ·  11-22 20:32
Lexicon Pharmaceuticals Inc: Efforts Expected to Reduce 2025 Operating Costs by $100 Mln
Lexicon Pharmaceuticals Inc: Receipt of a "Deficiencies Preclude Discussion" Letter From FDA Regarding Nda for Zynquista
THOMSON REUTERS  ·  11-22 20:32
Lexicon Pharmaceuticals Inc: Receipt of a "Deficiencies Preclude Discussion" Letter From FDA Regarding Nda for Zynquista
Lexicon Pharmaceuticals Appoints Ivan Cheung to Board
TIPRANKS  ·  11-21 05:33
Lexicon Pharmaceuticals Appoints Ivan Cheung to Board
Lexicon Appoints Ivan H. Cheung to Board of Directors
THOMSON REUTERS  ·  11-21 05:05
Lexicon Appoints Ivan H. Cheung to Board of Directors

Introduction

Company Name.
Lexicon Pharmaceuticals
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.
Issue price:
--